Almost half who quit gave cost or insurance as the reason
Among 288 US adults who quit inside a year, 47.6% stopped over cost or insurance, 14.6% over side effects and 1.7% because the weight loss disappointed them.
What the study found
Cost, not side effects, was behind almost half of stops
The reason people give is rarely the one the conversation assumes. Among 288 US adults who quit injectable semaglutide or tirzepatide inside a year, 47.6% stopped over cost or insurance, 14.6% over side effects they could not tolerate, and 1.7% because the weight loss disappointed them.
The caveat · One US health system, in a shortage
Everyone counted here had already stopped, so these are shares of people who quit and not of people who started. The reason came from what a clinician typed into the record rather than from asking the patient, and 11.1% had no reason recorded at all. Semaglutide and tirzepatide were counted together. One US health system, over a period that included the shortage.